Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of CYP1A2 Inhibition on BMS-986165 Pharmacokinetics in Healthy Participants
NCT03930602Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2019
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of deucravacitinib in plaque psoriasis (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration at 10 days, Area under the concentration-time curve from time zero to time of last quantifiable concentration at 10 days and 1 more. Started May 2019; status: completed.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03930602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03930602.